NCT05524519 is a NA clinical trial of Basic treatment in Major Depressive Disorder, sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University.

Who is sponsoring NCT05524519?

NCT05524519 is sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University.

What drugs are being tested in NCT05524519?

Interventions in NCT05524519: Basic treatment, PSA, TSA, CCA.

What condition does NCT05524519 study?

NCT05524519 studies Major Depressive Disorder.

Is NCT05524519 still recruiting?

NCT05524519 is currently completed. Last updated 22 August 2025.

Last reviewed 2025-08-22 · How we verify

NCT05524519

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder

Completed NA Last updated 22 August 2025

What this trial tests

NA trial testing Basic treatment in Major Depressive Disorder in 160 participants. Completed in 31 December 2023.

Timeline

1 November 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	160
Start date	1 November 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Basic treatment — full drug profile →
PSA
TSA
CCA

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

The Third Affiliated hospital of Zhejiang Chinese Medical University

Who can join

Adults 18 to 60, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acupoints are the stimulus points and reactive points for acupuncture to treat diseases. Therefore, this study is designed to detect the pain threshold and temperature of biological specificities of acupoints in healthy control (HC) participants and major depressive disorder (MDD) participants by using pressure pain threshold gauge (PTG) and infrared thermography (IRT). Based on the results of the PTG and IRT tests, the potentially superior acupoints for the treatment of MDD will be selected separately. Then, different acupoint groups selected based on different biological specificities tests will be used for clinical treatment to evaluate the clinical efficacy of intradermal acupuncture (IA) for MDD based on changes in the biological specificities of acupoints.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effective on intradermal acupuncture based on changes in biological specificity of acupoints for major depressive disorder: study protocol of a prospective, multicenter, randomized, controlled trial.
Tu M, Wu X, Qu S, Jin J, et al · · 2023 · cited 4× · PMID 37441145 · DOI 10.3389/fpsyt.2023.1183127

Verify or expand the search:

Other trials of Basic treatment

Trials testing the same drug.

NCT06942858 — Mechanisms of Deep Transcranial Magnetic Stimulation in Enhancing Cognitive-Behavioral Therapy for Anorexia Nervosa · NA · recruiting
NCT06152640 — A New Neuroregulatory Technology for the Therapy of AN Based on the Pathological Neural Network of ACC · NA · recruiting
NCT06255353 — Effect of Different Feeding Modes in Intracerebral Hemorrhage · NA · completed
NCT06058091 — RY_SW01 Cell Injection Therapy in Systemic Sclerosis · Phase 1, PHASE2 · recruiting
NCT06058078 — RY_SW01 Cell Injection Therapy in Active Lupus Nephritis · Phase 2 · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other The Third Affiliated hospital of Zhejiang Chinese Medical University trials

Trials by the same sponsor.

NCT07522567 — Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures · NA · not yet recruiting
NCT07496580 — Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia · NA · not yet recruiting
NCT07325045 — Biomechanical Study of Lever Positioning Manipulation on Scoliosis · NA · not yet recruiting
NCT07250308 — Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms · recruiting
NCT07308951 — Effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Quality of Life in Chronic Cancer Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05524519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Affiliated hospital of Zhejiang Chinese Medical University
Last refreshed: 22 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05524519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing